Review promising preliminary findings from a phase I/II trial assessing combination therapy with inotuzumab ozogamicin and bosutinib in patients with relapsed/refractory Philadelphia chromosome–positive ALL or CML in lymphoid blast phase.
No clear evidence of benefit associated with midostaurin maintenance therapy in this unplanned post hoc subset analysis of the RATIFY trial.
Observational study found that a TKI duration of 5.8 years and MR4 duration of 3.1 years decreased the likelihood of relapse for patients with CML discontinuing TKI therapy.
Azacitidine was well tolerated and significantly improved disease-free survival in older patients with anemia-refractory AML.
Results confirm strong prognostic value of NPM1/FLT3-ITD genotypes in AML, supporting 2017 ELN risk stratification criteria that include FLT3-ITD allelic burden.
Preliminary data suggest novel combination of gilteritinib and chemotherapy has antileukemic effect in FLT3-mutated AML with acceptable safety.
Ivosidenib, an investigational mutant IDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutated IDH1.
The combination of IDH inhibitors enasidenib or ivosidenib with standard 7 + 3 induction chemotherapy appears safe with response rates comparable to those expected with standard induction chemotherapy in patients with either de novo or secondary AML.
Study reported median event-free survival of 8.3 months in patients receiving nivolumab plus cytarabine and idarubicin with manageable safety profile.
After more than 1 year of follow-up, the combination of venetoclax plus low-dose cytarabine achieved a CR + CRi rate of 62% and a median OS of 11.4 months in elderly patients with AML who are unfit for chemotherapy.
Preliminary findings demonstrate that the CPX-351 liposomal formulation of cytarabine:daunorubicin is both safe and active at reduced and higher doses in patients with AML at high risk for death during induction chemotherapy.
Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone.
Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome–positive ALL.
In this expert analysis, Farhad Ravandi, MD, and B. Douglas Smith, MD, review the clinically relevant studies on the management of acute and chronic leukemias presented at the Hematology 2017 annual meeting.
This large prospective study shows that identification of residual leukemia by targeted next-generation sequencing of select mutations present in CR serves as a strong independent predictor for AML relapse and survival.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.